Ascendis Pharma A/S
ASND
$164.65
-$4.19-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 185.39M | 63.58M | 38.75M | 104.10M | 148.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 185.39M | 63.58M | 38.75M | 104.10M | 148.25M |
| Cost of Revenue | 14.95M | 12.31M | 12.34M | 8.22M | 20.95M |
| Gross Profit | 170.44M | 51.27M | 26.41M | 95.88M | 127.30M |
| SG&A Expenses | 85.51M | 76.77M | 79.98M | 72.50M | 68.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 184.98M | 169.94M | 182.18M | 157.45M | 187.66M |
| Operating Income | 408.30K | -106.36M | -143.43M | -53.35M | -39.41M |
| Income Before Tax | -39.85M | -107.93M | -117.48M | -139.53M | -87.30M |
| Income Tax Expenses | 1.16M | 1.12M | 246.50K | 2.72M | 6.23M |
| Earnings from Continuing Operations | -41.01M | -109.06M | -117.73M | -142.25M | -93.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.01M | -109.06M | -117.73M | -142.25M | -93.53M |
| EBIT | 408.30K | -106.36M | -143.43M | -53.35M | -39.41M |
| EBITDA | 1.72M | -101.55M | -138.71M | -48.49M | -37.65M |
| EPS Basic | -0.69 | -1.90 | -2.05 | -2.50 | -1.65 |
| Normalized Basic EPS | -0.42 | -1.17 | -1.28 | -1.53 | -0.96 |
| EPS Diluted | -0.69 | -1.90 | -2.05 | -2.50 | -1.65 |
| Normalized Diluted EPS | -0.42 | -1.17 | -1.28 | -1.53 | -0.96 |
| Average Basic Shares Outstanding | 59.79M | 57.54M | 57.35M | 56.88M | 56.56M |
| Average Diluted Shares Outstanding | 59.79M | 57.54M | 57.35M | 56.88M | 56.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
